Additional Antianginal and Anti-Ischemic Efficacy of Mibefradil in Patients Pretreated With a Beta Blocker for Chronic Stable Angina Pectoris

This publication has 21 references indexed in Scilit:

• Hemodynamic and Cardiac Effects of the Selective T-Type and L-Type Calcium Channel Blocking Agent Mibefradil in Patients With Varying Degrees of Left Ventricular Systolic Dysfunction
  Journal of the American College of Cardiology, 1996
• Antihypertensive Properties of the Novel Calcium Antagonist Mibefradil (Ro 40-5967)
  Hypertension, 1996
• Effects of a new calcium antagonist, mibefradil (Ro 40–5967), on silent ischemia in patients with stable chronic angina pectoris: A multicenter placebo-controlled study
  Journal of the American College of Cardiology, 1996
• Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: A multicenter, placebo-controlled study
  American Heart Journal, 1995
• The binding interactions of Ro 40-5967 at the L-type Ca2+ channel in cardiac tissue
  European Journal of Pharmacology, 1995
• Ro 40–5967: A New Nondihydropyridine Calcium Antagonist
  Cardiovascular Drug Reviews, 1991
• Ro 40–5967, in Contrast to Diltiazem, Does Not Reduce Left Ventricular Contractility in Rats with Chronic Myocardial Infarction
  Journal of Cardiovascular Pharmacology, 1991
• Hemodynamic Profile of Ro 40–5967 in Conscious Rats
  Journal of Cardiovascular Pharmacology, 1991
• The structurally novel Ca2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts
  Cardiovascular Drugs and Therapy, 1990
• In Vitro Pharmacologic Profile of Ro 40-5967, a Novel Ca2+ Channel Blocker with Potent Vasodilator but Weak Inotropic Action
  Journal of Cardiovascular Pharmacology, 1989